FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to ...

BioMarin has today announced Health Canada has granted a Notice of Compliance with Conditions (NOC/c) for PrVOXZOGO® (vosoritide for injection), the only approved medicine for eligible patients with ...

There's no need to hurry in buying this biotech stock.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Best Cheap Stocks to Buy Right Now. Barclays initiated coverage of BioMarin on January 28, assigning it an “Overweight” rating and a target ...

BioMarin Pharmaceutical (NasdaqGS:BMRN) announced a major debt financing package to support its pending acquisition of Amicus ...

US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) has priced an $850 million offering of 5.5% senior unsecured notes due 2034 ...

Shortly after taking the reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling hemophilia A gene therapy, Roctavian. A year after opting to shrink the ...

VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $950 million. Refer to Non-GAAP Information beginning on page 10 of this press release for ...

BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, ...

SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...

Those results were published just after market hours on Wednesday, and they showed that the company's revenue reached $747 million for its fourth quarter of 2024. That was a beefy (16%) increase over ...